On April 1, 2026, the FDA approved Eli Lilly's oral GLP-1 receptor agonist orforglipron under the brand name Foundayo. It's the first once-daily pill-form GLP-1 receptor agonist approved for chronic weight management — and the first that can be taken any time of day, without food or water restrictions.
For the millions of people on (or considering) weekly injectable GLP-1s like Ozempic, Wegovy, Mounjaro, and Zepbound, this is a meaningful change in the treatment landscape. Here's what Foundayo is, how it compares to the injectables, and what it means for supplement and nutrition planning.
What Is Foundayo (Orforglipron)?
Foundayo is a once-daily oral small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide (the active ingredient in Ozempic, Wegovy, and oral Rybelsus), orforglipron is not a peptide — it's a non-peptide small molecule. That's what makes it dosable as a standard oral pill without the absorption constraints that make Rybelsus require a strict fasting window.
Approved indication: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.
Dosing: Once daily, any time of day, with or without food or water.
Approved doses: 6 mg, 12 mg, and 36 mg (titrated up).
How It Compares to Ozempic, Wegovy, Mounjaro, and Zepbound
| Feature | Foundayo (orforglipron) | Ozempic / Wegovy (semaglutide) | Mounjaro / Zepbound (tirzepatide) |
|---|---|---|---|
| Form | Oral pill | Weekly injection | Weekly injection |
| Class | GLP-1 RA (small molecule) | GLP-1 RA (peptide) | GLP-1 + GIP RA (peptide) |
| Frequency | Once daily | Once weekly | Once weekly |
| Food/timing restrictions | None | None (Ozempic/Wegovy) | None |
| Average weight loss (max dose, ~72 wks) | ~12.4% (ATTAIN-1) | ~14.9% (STEP 1) | ~20.9% (SURMOUNT-1) |
| Top dose | 36 mg | 2.4 mg (Wegovy) | 15 mg (Zepbound) |
ATTAIN-1 Phase 3 Results
In the ATTAIN-1 trial (published NEJM, September 2025), orforglipron 36 mg produced: - Average weight loss of 12.4% (~27.3 lbs) vs 0.9% on placebo at 72 weeks - 54.6% of patients achieved ≥10% weight loss - 36.0% achieved ≥15% - 18.4% achieved ≥20%
Improvements in waist circumference, blood pressure, triglycerides, and non-HDL cholesterol paralleled the weight results.
Side Effect Profile: Familiar Territory
The orforglipron side-effect profile looks very similar to injectable GLP-1s — because it works on the same receptor.
From ATTAIN-1 (36 mg dose): - Nausea: ~33.7% - Constipation: ~25.4% - Diarrhea: ~23.1% - Vomiting: ~24.0% - Treatment discontinuation due to adverse events: 10.3%
Compared to semaglutide 2.4 mg in STEP 1 (nausea ~44%, constipation ~24%, vomiting ~24%) and tirzepatide 15 mg in SURMOUNT-1 (nausea ~29%, constipation ~17%, vomiting ~13%), orforglipron sits within the expected class range.
Key Takeaway: Foundayo is an oral alternative to injectable GLP-1s with efficacy closer to Wegovy than to Zepbound, and a comparable side-effect profile. Convenience is its main differentiator.
Why the Oral Formulation Matters
For many patients, the barrier to starting GLP-1 therapy isn't the medication itself — it's the injection. An oral daily pill removes:
- Needle anxiety
- Injection-site reactions
- Weekly cold-chain storage complexity
- The perception of "being on a shot"
At the same time, a daily pill requires a daily habit. For patients who forget meds or prefer set-and-forget weekly dosing, injectables still have an advantage.
What This Means for Supplement and Nutrition Needs
Because orforglipron works on the same GLP-1 receptor pathway, the downstream effects — reduced caloric intake, delayed gastric emptying, potential for muscle loss and nutrient gaps — are essentially the same as with injectable GLP-1s.
Orforglipron users should expect the same nutritional considerations:
- 1.Protein target of 1.2-1.6 g/kg/day to protect lean mass. See our muscle preservation guide.
- 2.Core five nutrient coverage — B12, D, iron, zinc, magnesium. See our nutrient deficiency guide.
- 3.Electrolyte and hydration support for fatigue, brain fog, and constipation. See our Hydrate page.
- 4.Side-effect playbooks for nausea, constipation, and GI symptoms apply identically. See our complete side effects guide.
In short: the medication form is new. The supplement needs aren't.
Who Might Choose Foundayo Over Injectables?
Good fits: - Patients with needle aversion - Patients who want daily (habit-based) rather than weekly dosing - Patients who travel frequently (no refrigeration needed for most orforglipron formulations) - Patients who want to trial GLP-1 therapy with a lower-commitment delivery
Less ideal fits: - Patients who struggle with daily medication adherence - Patients seeking maximum weight-loss magnitude (tirzepatide still shows the highest average weight loss in head-to-head comparisons) - Patients already doing well on weekly injections
Discuss the trade-offs with your prescriber.
The SQ[1] Perspective
Whether you're on Ozempic, Wegovy, Mounjaro, Zepbound, oral Rybelsus, or now Foundayo, the underlying physiology is similar: reduced appetite, slower gastric emptying, rapid weight loss, and the predictable nutritional gaps that come with eating 30-50% less food.
SQ[1] was built around that shared physiology — not around any single brand name. Our Daily Essentials, Protein, Hydrate, and Glow formulas support the metabolic reality of modern GLP-1 therapy regardless of which specific molecule you're taking.
FAQ
Is Foundayo the same as oral semaglutide (Rybelsus)?
No. Rybelsus is oral semaglutide — a peptide that requires a strict fasting window and specific water volume to absorb. Foundayo (orforglipron) is a non-peptide small molecule that can be taken any time, with or without food or water.
Is Foundayo covered by insurance?
Coverage is evolving. Early 2026 pricing and formulary placement differ across insurers. Check with your plan and pharmacy.
Can I switch from Ozempic to Foundayo?
Lilly ran a switch study showing patients transitioning from injectable incretins to oral orforglipron maintained their weight loss. Discuss transition timing with your prescriber.
Does Foundayo cause less nausea than Ozempic?
Side-effect rates are comparable but not identical. Individual variation is substantial. Most patients still experience some nausea in weeks 1-8.
Do I need different supplements on Foundayo vs Ozempic?
No. The nutritional needs of GLP-1 therapy — protein, electrolytes, the core five micronutrients — apply regardless of which GLP-1 medication you're taking.
This article is for educational purposes only. Foundayo is a prescription medication — discuss treatment decisions with your healthcare provider.
These statements have not been evaluated by the Food and Drug Administration. SQ[1] products are not intended to diagnose, treat, cure, or prevent any disease.
Support your GLP-1 journey, whichever medication you're on. Explore the SQ[1] system — built for the shared physiology of modern GLP-1 therapy.